Mourad Tayebi, PhD, Western Sydney University

Mourad Tayebi, PhD
Mourad Tayebi, PhD

Research in the Tayebi laboratory includes pharmacodynamics related to brain disorders. The Tayebi lab laid the groundwork for the development of unique and patented biologics effective in binding to soluble oligomeric species derived from a number of misfolded proteins, including Aβ, tau, prion, BACE, APP, α-synuclein and so on.

Products

References

  1. Rusbridge C, Salguero FJ, David MA, Faller KME, Bras JT, Guerreiro RJ, Richard-Londt AC, Grainger D, Head E, Brandner SGP, Summers B, Hardy J, Tayebi M. An Aged Canid with Behavioral Deficits Exhibits Blood and Cerebrospinal Fluid Amyloid Beta Oligomers. Front Aging Neurosci. 2018 Jan 30;10:7. doi: 10.3389/fnagi.2018.00007. PMID: 29441010; PMCID: PMC5797595.
  2. David MA, Jones DR, Tayebi M. Potential candidate camelid antibodies for the treatment of protein-misfolding diseases. J Neuroimmunol. 2014 Jul 15;272(1-2):76-85. doi: 10.1016/j.jneuroim.2014.05.001. Epub 2014 May 10. PMID: 24864011.
  3. Jones DR, Taylor WA, Bate C, David M, Tayebi M. A camelid anti-PrP antibody abrogates PrP replication in prion-permissive neuroblastoma cell lines. PLoS One. 2010;5(3):e9804. Published 2010 Mar 22. doi:10.1371/journal.pone.0009804